- Clinical diagnosis of stable mild-to-moderate plaque-type psoriasis involving 2-35% of
total body surface area (BSA) excluding face, scalp, and genitals
- Willingness and ability to apply study medication as directed, comply with study
instructions, and commit to attending all study visits
- Women of childbearing potential must agree to use contraception for the entire study
period
- Any dermatological conditions that could interfere with clinical evaluations
- Concurrent or recent use of certain topical or systemic medications without a
sufficient washout period
- Significant confounding conditions as assessed by study doctor
- Participated in any other trial of an investigational drug within 30 days or
participation in a research study concurrent with this study
- Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
- Use of a beta-blocking medication (e.g., propranolol) if the dose has not been
stabilized for at least 3 months
- Pregnancy or lactation